Przejdź do zawartości
Merck

The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring.

Expert opinion on pharmacotherapy (2007-08-10)
Marie-Soleil Wagner, Raquel D Arias, Deborah L Nucatola
ABSTRAKT

Many factors influence the effectiveness of contraceptive methods. Oral contraceptives are the second most popular contraceptive method after female sterilization in the US. A total of 25% of women do not use their oral contraceptives correctly; 30% of women do not use them consistently. Several new contraceptive methods with alternate routes of delivery and less frequent dosing are available. The combined etonogestrel/ethinyl estradiol contraceptive vaginal ring is marketed under the name of NuvaRing. This is the only contraceptive ring approved by the FDA. The administration of steroids by the vaginal route may offer many advantages. Because of less frequent dosing, self-administration, and possibly, an improved side effect profile, the ring has the potential to increase successful use.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
17α-Ethynylestradiol, ≥98%
Supelco
17α-Ethynylestradiol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Ethinylestradiol, European Pharmacopoeia (EP) Reference Standard
USP
Etynyloestradiol, United States Pharmacopeia (USP) Reference Standard
Supelco
Ethinyl Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material
Ethinylestradiol for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Etonogestrel, ≥98% (HPLC)